Loading...

Major Indexes

Financial Statements

Applied DNA Sciences Inc

Applied DNA Sciences Inc (APDN)

$8.25
0.5 (+6.45%)

Income Statement

Quarter data
Download APDN income statement Download APDN income statement Download APDN income statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Earnings Per Share Diluted 0.02-0.03-0.03-0.03-0.01-1.51-0.97-0.63-0.51-0.49-9.69
Net Profit Margin 13.36-15.22-10.85-10.85-3.86-8.69-4.80-1.32-2.91-2.71-1.60
Weighted Average Shares Outstanding 251,520.54300,352.91376.83376.833.203.203.203.203.203.203.20
Revenue 295.16519.840.970.971.852.042.729.014.194.755.39
Weighted Average Shares Outstanding (Diluted) 308,912.41300,352.91376.83376.83576.0911.7313.5218.9423.6926.380.92
Gross Profit 233.92456.920.970.971.852.042.728.623.023.674.51
Dividend per Share -----------
Operating Income -6,896.04-7,117.05-8.06-8.06-6.51-10.18-12.27-7.85-12.20-12.82-9.12
Gross Margin 0.790.881.001.001.001.001.000.960.720.770.84
Income Tax Expense ----1.422.960.6413.92--0.01
EBIT Margin -21.95-12.98-4.89-4.89-3.00-4.90-4.35-0.82-2.75-2.56-1.62
Net Income 3,944.58-7,909.60-10.52-10.52-7.15-17.69-13.07-11.88-12.18-12.86-8.62
Cost of Revenue 61.2462.93-----0.381.171.080.88
Earnings Before Tax Margin 13.37-15.22-10.85-10.85-3.86-8.69-4.80-1.32-2.91-2.71-1.60
EBIT -6,896.04-7,117.05-8.06-8.06-6.51-10.18-12.27-7.85-12.20-12.82-9.12
EBITDA -6,477.91-6,745.14-4.73-4.73-5.57-9.97-11.83-7.36-11.49-12.19-8.71
Profit Margin 13.36-15.22-10.85-10.85-3.86-8.69-4.80-1.32-2.91-2.71-1.60
Operating Expenses 7,129.977,573.979.039.038.3612.2114.9916.4815.2216.4913.64
Earnings Per Share Basic 0.02-0.03-0.03-0.03-0.01-1.51-0.97-0.63-0.51-0.49-9.69
Earnings before Tax 3,945.15-7,909.60-10.52-10.52-7.15-17.69-13.07-11.88-12.18-12.86-8.62
Interest Expense 1,182.69792.552.462.460.64------

Balance Sheet Statement

Quarter data
Download APDN balance shet statement Download APDN balance sheet statement Download APDN balance sheet statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Short-term debt 2,410.411,774.083.73--1.80---1,586.631.60
Other Assets 1,155.281,167.45382.2836.28471.94566.611,562.991,610.1161.6362.33172.05
Total current liabilities 3,253.902,791.634.500.591.123.882.674.081.302.822.25
Cash and cash equivalents 213.3117.622.750.726.361.397.314.482.961.660.56
Long-term debt -----1.800.32--1.591.44
Cash and short-term investments 213.3117.622.750.726.361.397.314.482.961.660.66
Total debt 2,410.411,774.083.73--3.600.32--1.593.05
Inventories -------0.300.330.220.14
Deferred revenue ----0.150.580.281.840.351.860.63
Goodwill and Intangible Assets --0.27-0.420.331.881.811.331.151.02
Total non-current liabilities -----1.800.320.90-1.591.44
Total non-current assets 11.743.770.470.251.171.144.024.211.911.631.42
Total liabilities 1,507.071,413.314.500.593.764.972.995.201.304.884.41
Total assets 1,507.071,413.313.501.358.373.5115.5515.578.155.633.56
Other comprehensive income --160.39169.76191.31198.29224.21234.16243.50249.09255.96
Short-term investments ----------0.10
Property, Plant & Equipment Net 11.743.770.090.210.700.580.570.790.520.420.23
Net Debt 2,197.101,756.460.98-0.72-6.362.21-6.99-4.48-2.96-0.072.49
Investments ----------0.10
Total shareholders equity -1,746.83-1,598.03-1.000.764.62-1.4712.5710.376.860.75-0.84
Retained earnings (deficit) ---161.86-169.01-186.69-199.76-211.64-223.82-236.67-248.37-256.81
Long-term investments -----------
Receivables 47.3063.030.210.300.670.833.936.372.591.490.84
Payables 843.49967.550.770.590.971.492.392.250.940.971.62
Total current assets 340.05242.103.031.107.212.3611.5411.356.244.002.15

Cash Flow Statement

Quarter data
Download APDN cash flow statement Download APDN cash flow statement Download APDN cash flow statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Investing Cash Flow ---0.09-0.09-0.16-1.22-0.23-2.14-0.78-0.15-0.07
Free Cash Flow -2,468.60-2,455.19-3.85-3.85-4.12-8.45-8.74-8.75-10.68-7.62-6.93
Depreciation & Amortization 418.13371.913.323.320.940.210.440.490.710.630.41
Net cash flow / Change in cash 76.90-195.692.732.73-2.025.64-4.975.92-2.83-1.52-1.10
Effect of forex changes on cash -----------
Financing Cash Flow 2,545.502,259.506.586.582.1014.733.7815.027.846.115.83
Dividend payments ----------309.61
Stock-based compensation 643.631,250.951.441.441.951.522.034.022.043.261.13
Investment purchases -----------
Acquisitions and disposals -----------
Capital Expenditure --0.090.090.160.580.231.790.790.150.07
Operating Cash Flow -2,468.60-2,455.19-3.76-3.76-3.96-7.87-8.51-6.97-9.90-7.48-6.86

Retained Earning Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) ----162-169-187-200-212-224-237-248
Net Income 3,945-7,910-11-11-7-18-13-12-12-13-9
Stock Dividends -3,9457,910-1513-1151-0-11-309
Dividend Paid ----------310
Retained Earnings ---162-169-187-200-212-224-237-248-257

PPE Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE 6412400111110
Annual Depreciation -52-8-400-1-0-2-1-0-0
Capital Expenditure --000102100
Net PPE 124001111100

Intangible and Goodwill Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) ---0-002211
New Purchases -----------
Intangible and Goodwill --0-0022111

Applied DNA Sciences Inc income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Applied DNA Sciences Inc FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.